Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective

BACKGROUND: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results (LEADER) clinical trial demonstrated that liraglutide added to standard-of-care (SoC) therapy for type 2 diabetes (T2D) with established cardiovascular disease (CVD) or elevated cardiovascular (C...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clinicoecon Outcomes Res
Autori principali: Shah, Dhvani, Risebrough, Nancy A, Perdrizet, Johnna, Iyer, Neeraj N, Gamble, Cory, Dang-Tan, Tam
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6241540/
https://ncbi.nlm.nih.gov/pubmed/30532570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S180067
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi